Surv-CRM-12: a Bayesian phase I/II survival CRM for right-censored toxicity endpoints with competing disease progression
From MaRDI portal
Publication:6629418
DOI10.1002/SIM.9591zbMATH Open1547.62126MaRDI QIDQ6629418
Shing M. Lee, [[Person:6068877|Author name not available (Why is that?)]], Sylvie Chevret, Anaïs Andrillon
Publication date: 30 October 2024
Published in: Statistics in Medicine (Search for Journal in Brave)
Cites Work
- A class of k-sample tests for comparing the cumulative incidence of a competing risk
- Dose-Finding Designs for HIV Studies
- Robust EM Continual Reassessment Method in Oncology Dose Finding
- Sequential Implementation of Stepwise Procedures for Identifying the Maximum Tolerated Dose
- A nonidentifiability aspect of the problem of competing risks.
- Continual Reassessment Method: A Likelihood Approach
- A Strategy for Dose-Finding and Safety Monitoring Based on Efficacy and Adverse Outcomes in Phase I/II Clinical Trials
- Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities
- Simple benchmark for complex dose finding studies
- Competing risks as a multi-state model
- Non-parametric optimal design in dose finding studies
- Direct Parametric Inference for the Cumulative Incidence Function
- A Bayesian adaptive phase I/II clinical trial design with late‐onset competing risk outcomes
- Seamless phase I/II design for novel anticancer agents with competing disease progression
This page was built for publication: Surv-CRM-12: a Bayesian phase I/II survival CRM for right-censored toxicity endpoints with competing disease progression
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q6629418)
